Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.
Animals
Chimerism
Disease Models, Animal
Hematopoietic Stem Cell Transplantation
Heterografts
Humans
Immune System
Immunotherapy
/ adverse effects
Lymphocyte Subsets
/ immunology
Lymphoid Tissue
/ immunology
Mice
Mice, Inbred NOD
Mice, Knockout
Mice, SCID
Neoplasms
/ etiology
Phenotype
Xenograft Model Antitumor Assays
PDX (patient derived xenograft)
TME (tumor microenvironment)
checkpoint blockade
combination testing
humanized mice
immune correlates
immunotherapy
preclinical model
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
09
2020
accepted:
04
03
2021
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Over the past decade, immunotherapies have revolutionized the treatment of cancer. Although the success of immunotherapy is remarkable, it is still limited to a subset of patients. More than 1500 clinical trials are currently ongoing with a goal of improving the efficacy of immunotherapy through co-administration of other agents. Preclinical, small-animal models are strongly desired to increase the pace of scientific discovery, while reducing the cost of combination drug testing in humans. Human immune system (HIS) mice are highly immune-deficient mouse recipients rtpeconstituted with human hematopoietic stem cells. These HIS-mice are capable of growing human tumor cell lines and patient-derived tumor xenografts. This model allows rapid testing of multiple, immune-related therapeutics for tumors originating from unique clinical samples. Using a cord blood-derived HIS-BALB/c-Rag2
Identifiants
pubmed: 33854497
doi: 10.3389/fimmu.2021.607282
pmc: PMC8040953
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
607282Subventions
Organisme : NIAID NIH HHS
ID : R01 AI143261
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA229174
Pays : United States
Organisme : NCI NIH HHS
ID : R33 CA191245
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA222620
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA229259
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI124474
Pays : United States
Informations de copyright
Copyright © 2021 Marín-Jiménez, Capasso, Lewis, Bagby, Hartman, Shulman, Navarro, Yu, Rivard, Wang, Barkow, Geng, Kar, Yingst, Tufa, Dolan, Blatchford, Freed, Torres, Davila, Slansky, Pelanda, Eckhardt, Messersmith, Diamond, Lieu, Verneris, Wang, Kiseljak-Vassiliades, Pitts and Lang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncogene. 2016 Jan 21;35(3):290-300
pubmed: 25893296
Lancet Oncol. 2020 Sep;21(9):e419-e430
pubmed: 32888471
J Clin Endocrinol Metab. 2020 Jan 1;105(1):
pubmed: 31513709
J Virol. 2018 Oct 12;92(21):
pubmed: 30089703
Nat Rev Clin Oncol. 2014 Sep;11(9):509-24
pubmed: 25001465
Front Immunol. 2017 Dec 08;8:1709
pubmed: 29276513
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32217760
Cancers (Basel). 2020 Apr 30;12(5):
pubmed: 32365882
Life Sci Alliance. 2019 Apr 1;2(2):
pubmed: 30936185
Leukemia. 2010 Oct;24(10):1785-8
pubmed: 20686503
PLoS One. 2018 Nov 2;13(11):e0206223
pubmed: 30388137
Int Immunol. 2007 Jul;19(7):813-24
pubmed: 17606980
Hum Immunol. 2009 Oct;70(10):790-802
pubmed: 19524633
Haematologica. 2016 Jan;101(1):5-19
pubmed: 26721800
Nat Med. 2018 Aug;24(8):1178-1191
pubmed: 29942093
Oncotarget. 2016 Feb 9;7(6):6448-59
pubmed: 26824989
Nat Methods. 2018 Aug;15(8):623-630
pubmed: 30065364
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
Chest. 2013 Jan;143(1):146-151
pubmed: 22847040
Am Soc Clin Oncol Educ Book. 2020 May;40:e344-e350
pubmed: 32511030
Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13224-9
pubmed: 21788504
J Immunol. 2014 Jul 15;193(2):587-96
pubmed: 24943216
Biochem Pharmacol. 2020 Apr;174:113671
pubmed: 31634456
Cell Res. 2020 Apr;30(4):285-299
pubmed: 31974523
J Immunol. 2011 Oct 1;187(7):3895-903
pubmed: 21876039
MAbs. 2014 Jul-Aug;6(4):968-77
pubmed: 24870377
Cell Rep. 2020 May 5;31(5):107588
pubmed: 32375033
Nat Protoc. 2020 Jan;15(1):15-39
pubmed: 31853056
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Front Immunol. 2020 Jan 10;10:3051
pubmed: 31998319
Clin Exp Immunol. 2008 Nov;154(2):270-84
pubmed: 18785974
Cell. 2019 Jan 24;176(3):677
pubmed: 30682374
J Exp Med. 2009 Jun 8;206(6):1423-34
pubmed: 19487422
Toxicol Sci. 2019 May 1;169(1):194-208
pubmed: 30850839
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
PLoS Pathog. 2016 May 17;12(5):e1005642
pubmed: 27186886
J Immunol. 2004 Mar 1;172(5):2731-8
pubmed: 14978070
Sci Rep. 2016 Aug 02;6:30723
pubmed: 27480578
Stem Cell Reports. 2016 Oct 11;7(4):591-601
pubmed: 27618723
Blood Adv. 2017 Dec 19;1(27):2729-2741
pubmed: 29296925
Science. 2004 Apr 2;304(5667):104-7
pubmed: 15064419
Mol Ther Oncolytics. 2019 Nov 29;16:41-52
pubmed: 31930165
J Immunol. 2005 May 15;174(10):6477-89
pubmed: 15879151
Front Immunol. 2017 Feb 06;8:86
pubmed: 28220123
Trends Immunol. 2017 Jan;38(1):20-28
pubmed: 27793572
Cancer Immunol Res. 2019 Aug;7(8):1237-1243
pubmed: 31171504
Clin Cancer Res. 2017 Jan 1;23(1):149-158
pubmed: 27458246
Front Immunol. 2018 Jan 26;9:54
pubmed: 29434589
Blood. 2002 Nov 1;100(9):3175-82
pubmed: 12384415
Clin Cancer Res. 2018 Oct 15;24(20):4960-4967
pubmed: 29685882
Mol Carcinog. 2020 Jul;59(7):862-870
pubmed: 32386086
Stem Cell Reports. 2015 Feb 10;4(2):171-80
pubmed: 25601207
Nat Commun. 2017 Sep 27;8(1):707
pubmed: 28955032
EMBO Mol Med. 2020 Jul 7;12(7):e8662
pubmed: 32578942
Blood. 2011 Mar 17;117(11):3076-86
pubmed: 21252091
Nat Rev Clin Oncol. 2016 Jun;13(6):394
pubmed: 27118494
Ann Oncol. 2016 Jul;27(7):1190-8
pubmed: 26912558
BMC Cancer. 2020 Nov 4;20(1):1063
pubmed: 33148223
Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9626-E9634
pubmed: 29078283
Annu Rev Immunol. 2001;19:565-94
pubmed: 11244047
Immunobiology. 2014 Feb;219(2):131-7
pubmed: 24094417
Exp Mol Med. 2018 Aug 7;50(8):1-9
pubmed: 30089794
Br J Cancer. 2019 Jul;121(2):101-108
pubmed: 31231121
Immunol Rev. 2016 Jan;269(1):118-29
pubmed: 26683149
Microbiol Spectr. 2019 Mar;7(2):
pubmed: 30953434
Annu Rev Pathol. 2017 Jan 24;12:187-215
pubmed: 27959627
J Immunother Cancer. 2018 Dec 4;6(1):140
pubmed: 30514385
Blood. 2013 Feb 21;121(8):1316-25
pubmed: 23293079
Nat Commun. 2019 Jan 21;10(1):366
pubmed: 30664659
J Intern Med. 2018 Feb;283(2):110-120
pubmed: 29071761
J Immunother Cancer. 2019 Feb 8;7(1):37
pubmed: 30736857
Curr Opin Virol. 2016 Aug;19:56-64
pubmed: 27447446
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Sci Transl Med. 2012 Mar 14;4(125):125ra30
pubmed: 22422991
Int J Mol Sci. 2020 Jun 09;21(11):
pubmed: 32526987
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2946-51
pubmed: 23382184
Cell Immunol. 2017 Nov;321:8-17
pubmed: 28838763
J Immunol. 2013 Mar 1;190(5):2090-101
pubmed: 23335750
Sci Rep. 2016 Jun 21;6:28093
pubmed: 27323875
Int Immunol. 2009 Jul;21(7):843-58
pubmed: 19515798
Cancers (Basel). 2020 Jul 15;12(7):
pubmed: 32679920
Transl Oncol. 2020 Mar;13(3):100745
pubmed: 32092671
Cell. 2016 Dec 1;167(6):1540-1554.e12
pubmed: 27912061
Blood. 2003 Oct 1;102(7):2522-31
pubmed: 12791667
Clin Immunol. 2010 Apr;135(1):84-98
pubmed: 20096637
Breast Cancer Res. 2018 Sep 5;20(1):108
pubmed: 30185216
Am J Clin Exp Urol. 2019 Oct 15;7(5):313-320
pubmed: 31763362
Cancer Res. 2016 Nov 1;76(21):6153-6158
pubmed: 27587540
Eur J Immunol. 2019 Jun;49(6):954-965
pubmed: 30888052
Trends Immunol. 2020 Aug;41(8):652-664
pubmed: 32654925
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
Cancer Sci. 2018 Oct;109(10):3032-3042
pubmed: 30066977
NPJ Genom Med. 2017;2:
pubmed: 28819565
Blood Adv. 2017 Apr 06;1(10):601-614
pubmed: 29296702
Nat Med. 2019 Mar;25(3):389-402
pubmed: 30842677
J Clin Invest. 2017 Apr 3;127(4):1392-1404
pubmed: 28240602
Mamm Genome. 2019 Jun;30(5-6):123-142
pubmed: 30847553
Annu Rev Immunol. 2013;31:635-674
pubmed: 23330956
Cancer Discov. 2018 Feb;8(2):196-215
pubmed: 29101162
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Oncol Rep. 2010 Oct;24(4):1067-72
pubmed: 20811690
Cancer Immunol Res. 2018 Dec;6(12):1445-1452
pubmed: 30510057
J Immunother Cancer. 2019 Aug 5;7(1):205
pubmed: 31383005
Nat Commun. 2018 Nov 28;9(1):5031
pubmed: 30487575
Blood. 2010 Nov 18;116(20):4158-67
pubmed: 20671122
Nat Rev Immunol. 2018 Aug;18(8):498-513
pubmed: 29743717
Cell. 2018 Oct 4;175(2):416-428.e13
pubmed: 30245014
Clin Immunol. 2011 Jul;140(1):102-16
pubmed: 21536497
Transplantation. 2012 Dec 15;94(11):1095-102
pubmed: 23222735
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Front Immunol. 2018 May 04;9:847
pubmed: 29780381
Cancer Discov. 2018 Nov;8(11):1358-1365
pubmed: 30309862
Immunol Cell Biol. 2015 Sep;93(8):716-26
pubmed: 25744551
Front Immunol. 2018 Apr 20;9:746
pubmed: 29755454
Ann Oncol. 2018 Jan 1;29(1):71-83
pubmed: 29069302
Cancer Immunol Res. 2019 Aug;7(8):1318-1331
pubmed: 31235619
Front Immunol. 2020 Mar 04;11:364
pubmed: 32194568
BMC Immunol. 2017 May 30;18(1):28
pubmed: 28558649
Cancer Immunol Res. 2017 Sep;5(9):790-803
pubmed: 28775208
Cancer Cell. 2019 Nov 11;36(5):471-482
pubmed: 31715131
Clin Cancer Res. 2017 Nov 1;23(21):6650-6660
pubmed: 28751450
Cell Res. 2020 Jun;30(6):507-519
pubmed: 32467593
Biol Open. 2015 Sep 09;4(10):1243-52
pubmed: 26353862
J Infect Dis. 2013 Nov;208 Suppl 2:S155-9
pubmed: 24151323
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
FASEB J. 2018 Mar;32(3):1537-1549
pubmed: 29146734
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32034066
Immunology. 2018 May;154(1):50-61
pubmed: 29446074
Cancers (Basel). 2020 Jun 18;12(6):
pubmed: 32570871
Cancer Med. 2018 Sep;7(9):4509-4516
pubmed: 30039553
Mol Oncol. 2018 Oct;12(10):1797-1810
pubmed: 30120895